BioCentury
ARTICLE | Clinical News

Kyowa PD drug misses in global Phase III

December 13, 2016 11:08 PM UTC

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said istradefylline (KW-6002) missed the primary endpoint in a global Phase III trial to treat moderate to severe Parkinson’s disease in patients with "wearing-off" phenomena on levodopa therapy. Compared with placebo, neither of two doses of the candidate significantly reduced daily "off"-time from baseline to week 12.

Kyowa said it hopes to work with FDA to discuss a possible submission. The company had an SPA from FDA for the trial...

BCIQ Company Profiles

Kyowa Kirin Co. Ltd.